Skip to main content
. 2022 Jul 2;40(7):699–714. doi: 10.1007/s40273-022-01168-0

Table 7.

Overall QALY, cost, and ICER estimates for molnupiravir versus best supportive care, in the base-case analysis

Treatment Total discounted QALYs Total discounted costs Incremental QALYs (molnupiravir vs. BSC) Incremental costs (molnupiravir vs. BSC) ICER (molnupiravir vs. BSC)
Molnupiravir 17.721 $8795 0.210 −$895 Dominating
BSC 17.512 $9690

BSC best supportive care, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years